Search clinical trials for: ESBA1008 solution

Total 19134 results

Alcon Research

Completed

ESBA105 in Patients With Severe Dry Eye

Eyes Dry Chronic

United States
ESBATech AG

Completed

Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis

Anterior Uveitis

Germany
ESBATech AG

Completed

Study of ESBA105 Eye Drops in Healthy Subjects

Healthy

Switzerland
Alcon Research

Completed

ESBA1008 Microvolume Study

Exudative Age-Related Macular Degeneration
Alcon Research

Completed

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Exudative Age-Related Macular Degeneration
Alcon Research

Completed

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

Exudative Age-Related Macular Degeneration
Alcon Research

Completed

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (BUZZARD)

Diabetic Macula Edema
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery (DRIFTER)

Type 2 Diabetes | Bariatric Surgery

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)

Diabetic Macular Edema

United States, Hungary, Israel, Slovakia, Puerto Rico
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)

Diabetic Macular Edema

United States, Austria, Japan, Australia, Spain, Canada, Israel, Netherlands, Italy, United Kingdom, Portugal, Colombia, Puerto Rico, Argentina
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes

United States
Baskent University

Unknown

Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery

Myocardial Injury

Turkey
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
ORA, Inc.
Palatin Technologies, Inc

Completed

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Dry Eye Disease

United States
Mimetogen Pharmaceuticals USA, Inc.

Active, not recruiting

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes | Dry Eye Disease | Kerato Conjunctivitis Sicca

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Keratoconjunctivitis Sicca

United States
Washington University School of Medicine
Quest Medical, Inc

Recruiting

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

Aortic Valve Disease | Mitral Valve Disease

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
HanAll BioPharma Co., Ltd.

Completed

A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes (VELOS-1)

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aerpio Therapeutics

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
VivaVision Biotech, Inc

Not yet recruiting

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

Dry Eye

China
Sylentis, S.A.

Completed

Safety Study of Tivanisiran to Treat Dry Eye (FYDES)

Dry Eye Disease

United States
The Hospital for Sick Children

Completed

Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal

Chronic Dialysis Patients

Canada
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Meiji Seika Pharma Co., Ltd.

Completed

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Onychomycosis

United States
Herantis Pharma Plc.
ORA, Inc.

Completed

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Dry Eye Syndrome

United States
Santen Pharmaceutical Asia Pte. Ltd.

Recruiting

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NOPAPS)

Ocular Hypertension | Primary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma, Suspect

Korea, Republic of
Sylentis, S.A.

Completed

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

Dry Eye Disease | Sjögren Syndrome

United States, Spain
ORA, Inc.
Topivert Pharma Ltd

Completed

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Dry Eye Syndrome

United States
Kyushu University

Completed

PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity

Japan
Dong-A University
Baxter Healthcare Corporation

Completed

Effect of Extraneal (Icodextrin) on Triglyceride Levels in PD Patients

End Stage Renal Disease

Korea, Republic of

3

Subscribe